Bio-Path Holdings, Inc.
(NASDAQ : BPTH)

( )
BPTH PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen Inc.
-0.91%195.591.2%$518.97m
GILDGilead Sciences, Inc.
-1.10%72.780.9%$459.77m
BIIBBiogen Inc.
-0.76%328.411.3%$384.66m
CELGCelgene Corporation
-0.91%81.831.2%$339.18m
ILMNIllumina, Inc.
-2.57%313.413.5%$297.65m
REGNRegeneron Pharmaceuticals, Inc.
-1.72%377.552.6%$228.49m
ALXNAlexion Pharmaceuticals, Inc.
-0.37%121.492.0%$215.08m
VRTXVertex Pharmaceuticals Incorporated
-2.02%177.651.9%$210.48m
SRPTSarepta Therapeutics, Inc.
0.64%131.3416.4%$171.12m
AAgilent Technologies, Inc.
-0.92%65.631.5%$157.48m
BMRNBioMarin Pharmaceutical Inc.
-0.06%99.454.4%$135.37m
LGNDLigand Pharmaceuticals Incorporated
-1.24%200.0723.3%$115.36m
VKTXViking Therapeutics, Inc.
-1.80%14.200.9%$112.03m
NKTRNektar Therapeutics
0.35%49.085.6%$109.05m
EXASExact Sciences Corporation
-2.16%65.7725.3%$103.02m

Company Profile

Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company utilizing a novel technology that achieves systemic delivery for target specific protein inhibition for any gene product that is over-expressed in disease. Its platform DNAbilize, uses P-ethoxy, which is a deoxyribonucleic acid backbone modification that is intended to protect the DNA from destruction by the body's enzymes when circulating in vivo, incorporated inside of a neutral charged lipid bilayer. The company was founded by Peter Nielsen, Douglas P. Morris, Gabriel Lopez-Berestein and Ana Maria Tari on May 10, 2007 and is headquartered in Bellaire, TX.